New 'Four-in-One' antibody takes on tough lymphoma

NCT ID NCT05623982

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 21 times

Summary

This study tests a new drug called GNC-038, a special antibody that targets cancer from four different angles. It is for people with Non-Hodgkin's lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 40 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Harbin First Hospital

    RECRUITING

    Haerbin, Heilongjing, China

    Contact

  • Qingdao Central Hospital

    RECRUITING

    Qingdao, Shandong, China

    Contact

Conditions

Explore the condition pages connected to this study.